Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Recent developments at Burnham Institute for Medical Research

New antibiotics for methicillin-resistant Staphylococcus aureus (MRSA) and other pesky bacteria. Andrei Osterman and collaborators have used comparisons of bacterial genomes to identify new targets for antibiotics and produced first-generation chemical inhibitors of a class of bacterial enzymes, called NadDs (nicotinate mononucleotide adenylyltransferases).

17 Nov 2009

deCODE genetics files voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code

deCODE genetics, Inc. (Nasdaq: DCGN) today announced that it has filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code with the United States Bankruptcy Court for the District of Delaware to facilitate the sale of substantially all of its assets. deCODE is continuing to operate its business and manage its properties as a debtor-in-possession pursuant to Sections 1107 and 1108 of the Bankruptcy Code.

17 Nov 2009

Trustmark Voluntary Benefit Solutions offers coverage for vaccines including H1N1 to its policyholders

Trustmark Voluntary Benefit Solutions, a leading provider of payroll-deducted voluntary benefits, is now covering vaccines including H1N1 (swine flu).

17 Nov 2009

Talend bags orders from several global healthcare customers

Talend, the recognized market leader in open source data integration software, today announced several global healthcare customer wins including Children’s Hospital & Medical Center of Omaha, Hosta, The Clermont-Ferrand Hospital and The University for Health Sciences, Medical Informatics and Technology (UMIT). The traction gained in this space further validates Talend’s ability to provide scalable and flexible solutions at an affordable cost to healthcare organizations of all sizes, while satisfying the need for the real-time data the industry demands.

16 Nov 2009

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

Hollis-Eden Pharmaceuticals, Inc., today reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). Presented at the Molecular Targets and Cancer Therapeutics Conference, which is co-sponsored by the AACR, NCI and EORTC, the poster is titled: "Results of preclinical and clinical Phase I/II open-label dose-ranging trial with HE3235, a synthetic adrenal hormone, in Castrate Resistant Prostate Cancer (CRPC)."

16 Nov 2009

First-quarter fiscal 2010 results announced by IsoRay

IsoRay Inc. a medical isotope company focusing on the treatment of prostate, lung, head and neck and other malignant disease through the use of its proprietary radioisotope technology, announced its financial results for the first quarter of fiscal year 2010, ended September 30, 2009.

16 Nov 2009

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

Genta Incorporated today announced financial results for the quarter and nine months ended September 30, 2009. The Company also announced a restructuring, reduction in workforce, and re-ordering of clinical development priorities.

16 Nov 2009

Protox Therapeutics announces financial results for the third quarter ended September 30, 2009

Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced financial results for the third quarter, ended September 30, 2009.

16 Nov 2009

Inovio Biomedical reports financial results for the three and nine months ended September 30, 2009

Inovio Biomedical Corporation today reported financial results for the three and nine months ended September 30, 2009.

16 Nov 2009

Just one test not enough to detect heart defects in young athletes

To best detect early signs of life-threatening heart defects in young athletes, screening programs should include both popular diagnostic tests, not just one of them, according to new research from heart experts at Johns Hopkins.

16 Nov 2009

El Camino Hospital moves into new, technologically and seismically advanced facility

El Camino Hospital, the hospital of Silicon Valley, today completed its move into the new, technologically and seismically advanced facility. After completing several practice runs led by the activation team, hospital officials report all patients were safely transferred to the new facility.

16 Nov 2009

Veterans' health: Measuring the scope of mental health challenges

NPR profiles retired General Eric Shinseki, the head of the Department of Veterans Affairs, and his efforts to measure the scope of veterans' mental health issues. In his first nine months in this position, he "has spent hours just listening to veterans talk. Shinseki tells NPR's Steve Inskeep that he feels a strong obligation to 'give back' to the men and women he once served with." NPR reports on the task Shinseki faces: "Since 2001, more than 1 million new veterans have come into a system that is being stretched thin." One of Shinseki's missions to improve the care and resources available to these vets is to work with the Department of Defense to "create a computer-driven system that will track service personnel through their careers — including when they become veterans.

13 Nov 2009

Third quarter 2009 financial results announced by Soligenix

Soligenix, Inc., (Soligenix or the Company) (OTC Bulletin Board: SNGX), formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today its financial results for the third quarter of 2009.

13 Nov 2009

Ipsen receives marketing authorization in France for its 6-month sustained-release formulation of Decapeptyl

Ipsen, an innovation-driven global specialty pharmaceutical Group announces that the French regulatory authorities (Agence Française de Sécurité Sanitaire des Produits de Santé, AFSSAPS) have today granted the marketing authorization to the 6-month sustained-release formulation of Decapeptyl® (triptorelin embonate 22.5 mg) for the treatment of locally advanced and metastatic prostate cancer.

13 Nov 2009

Endo Pharmaceuticals reaches patent litigation settlement with LecTec

Endo Pharmaceuticals announced today that it has reached a settlement with LecTec Corporation on outstanding patent litigation related to LecTec's U.S. Patent Nos. 5,536,263 and 5,741,510.

11 Nov 2009

New robotic surgical systems from El Camino Hospital

El Camino Hospital, the hospital of Silicon Valley, expands its minimally invasive surgical program to three da Vinci® Si HD Surgical Systems. Physicians performed more than 500 robotic surgeries over the past year and expect the number to increase in 2010 as more physicians undergo training with the enhanced equipment that allows for more minimally invasive procedures.

11 Nov 2009

Cancer screening methods are not perfect: Experts

In a recent New York Times article, the American Cancer Society (ACS) ignited a major controversy over the benefits of cancer screening, specifically with regards to their breast and prostate cancer guidelines. In the article, Dr. Otis Brawley, chief medical officer of the ACS, responded to a study in the current issue of the Journal of the American Medical Association.

11 Nov 2009

Prostate size growth not necessarily a predictor of development of cancer

New Mayo Clinic research studied the association between prostate-specific antigen (PSA) levels and prostate size and found that routine annual evaluation of prostate growth is not necessarily a predictor for the development of prostate cancer. However the study suggests that if a man's PSA level is rising quickly, a prostate biopsy is reasonable to determine if he has prostate cancer.

11 Nov 2009

Researchers find link between two genes involved in cancer formation in humans

Researchers at Queen's University have found a link between two genes involved in cancer formation in humans, by examining the genes in worms. The groundbreaking discovery provides a foundation for how tumor-forming genes interact, and may offer a drug target for cancer treatment.

11 Nov 2009

Poniard Pharmaceuticals to present picoplatin Phase 2 trial data at the AACR-NCI -EORTC conference

Poniard Pharmaceuticals, Inc. today announced that the Company will present updated clinical data from its randomized, controlled Phase 2 trial of picoplatin in patients with metastatic colorectal cancer (CRC) and final results from its Phase 1 cardiac safety trial.

11 Nov 2009

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Recent developments at Burnham Institute for Medical Research

deCODE genetics files voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code

Trustmark Voluntary Benefit Solutions offers coverage for vaccines including H1N1 to its policyholders

Talend bags orders from several global healthcare customers

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

First-quarter fiscal 2010 results announced by IsoRay

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

Protox Therapeutics announces financial results for the third quarter ended September 30, 2009

Inovio Biomedical reports financial results for the three and nine months ended September 30, 2009

Just one test not enough to detect heart defects in young athletes

El Camino Hospital moves into new, technologically and seismically advanced facility

Veterans' health: Measuring the scope of mental health challenges

Third quarter 2009 financial results announced by Soligenix

Ipsen receives marketing authorization in France for its 6-month sustained-release formulation of Decapeptyl

Endo Pharmaceuticals reaches patent litigation settlement with LecTec

New robotic surgical systems from El Camino Hospital

Cancer screening methods are not perfect: Experts

Prostate size growth not necessarily a predictor of development of cancer

Researchers find link between two genes involved in cancer formation in humans

Poniard Pharmaceuticals to present picoplatin Phase 2 trial data at the AACR-NCI -EORTC conference

What to know about prostate cancer eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in